[en] Thrombocytopenia is commonly seen in patients receiving linezolid for >14 days. Linezolid is a reversible inhibitor of mitochondrial function in various cell types. This study investigated the inhibitory effects of linezolid and tedizolid, and their potential recovery on (i) CYTox I expression (subunit I of cytochrome c-oxidase; encoded by the mitochondrial genome), (ii) cytochrome c-oxidase activity and (iii) mitochondrial respiration (Seahorse bioanalysis) in two megakaryocytic cell lines [UT-7 WT (human acute megakaryoblastic leukaemia cells) and UT-7 MPL (transduced to express the thrombopoietin receptor)]. Cells were exposed to linezolid (0.5-25 mg/L) or tedizolid (0.1-5 mg/L) for up to 5 days and recovery followed after drug removal. Both oxazolidinones caused concentration- and time-dependent inhibition of CYTox I expression, cytochrome c-oxidase activity and mitochondrial spare capacity. On electron microscopy, mitochondria appeared dilated with a loss of cristae. Globally, tedizolid exerted stronger effects than linezolid. While CYTox I expression recovered completely after 6 days of drug washout, only partial (linezolid) or no (tedizolid) recovery of cytochrome c-oxidase activity, and no rescue of mitochondrial spare capacity (after 3 days) was observed. Thus, and in contrast to previous studies using a variety of cell lines unrelated to megakaryocytic lineages, the inhibitory effects exerted by oxazolidinones on the mitochondrial function of megakaryoblastic cells appear to be particularly protracted. Given the dynamics of platelet production and destruction, these results may explain why oxazolidinone-induced thrombocytopenia is one of the most common side effects in patients exposed to these antibiotics.
Disciplines :
Microbiology
Author, co-author :
Milosevic, Tamara V.
VERTENOEIL, Gaëlle ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'hématologie clinique
Payen, Valéry L.
Sonveaux, Pierre
Tulkens, Paul M.
Constantinescu, Stefan N.
Van Bambeke, Françoise
Language :
English
Title :
Prolonged inhibition and incomplete recovery of mitochondrial function in oxazolidinone-treated megakaryoblastic cell lines.
Wilson D.N., Schluenzen F., Harms J.M., Starosta A.L., Connell S.R., Fucini P.The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci USA2008;105:13339–44.
Chen K.H., Huang Y.T., Liao C.H., Sheng W.H., Hsueh P.R.In vitro activities of tedizolid and linezolid against Gram-positive cocci associated with acute bacterial skin and skin structure infections and pneumonia. Antimicrob Agents Chemother2015;59:6262–5.
Natsumoto B., Yokota K., Omata F., Furukawa K.Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection2014;42:1007–12.
Hanai Y., Matsuo K., Ogawa M., Higashi A., Kimura I., Hirayama S., et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother2016;22:536–42.
Nukui Y., Hatakeyama S., Okamoto K., Yamamoto T., Hisaka A., Suzuki H., et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother2013;68:2128–33.
Hardalo C., Lodise T.P., Bidell M., Flanagan S., De Anda C., Anuskiewicz S., et al. Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections. Expert Opin Drug Saf2018;17:359–67.
Lee E.Y., Caffrey A.R.Thrombocytopenia with tedizolid and linezolid. Antimicrob Agents Chemother2017;62:pii:e01453-17.
Nagiec E.E., Wu L., Swaney S.M., Chosay J.G., Ross D.E., Brieland J.K., et al. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob Agents Chemother2005;49:3896–902.
Milosevic T.V., Payen V.L., Sonveaux P., Muccioli G.G., Tulkens P.M., Van Bambeke F.Mitochondrial Alterations (Inhibition of Mitochondrial Protein Expression, Oxidative Metabolism, and Ultrastructure) Induced by Linezolid and Tedizolid at Clinically Relevant Concentrations in Cultured Human HL-60 Promyelocytes and THP-1 Monocytes. Antimicrob Agents Chemother 2018 Mar;62(3) pii: e01599-17 - PM:29263063.
Leach K.L., Swaney S.M., Colca J.R., McDonald W.G., Blinn J.R., Thomasco L.M., et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell2007;26:393–402.
Im W.B., Choi S.H., Park J.Y., Choi S.H., Finn J., Yoon S.H.Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur J Med Chem2011;46:1027–39.
Flanagan S., Fang E., Munoz K.A., Minassian S.L., Prokocimer P.G.Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacotherapy2014;34:891–900.
Komatsu N., Nakauchi H., Miwa A., Ishihara T., Eguchi M., Moroi M., et al. Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3, or erythropoietin for growth and survival. Cancer Res1991;51:341–8.
Besancenot R., Roos-Weil D., Tonetti C., Abdelouahab H., Lacout C., Pasquier F., et al. JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. Blood2014;124:2104–15.
De Vriese A.S., Coster R.V., Smet J., Seneca S., Lovering A., Van Haute L.L., et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis2006;42:1111–7.
Kadenbach B., Huttemann M.The subunit composition and function of mammalian cytochrome c oxidase. Mitochondrion2015;24:64–76.
Huang R., Zhao L., Chen H., Yin R.H., Li C.Y., Zhan Y.Q., et al. Megakaryocytic differentiation of K562 cells induced by PMA reduced the activity of respiratory chain complex IV. PLoS One2014;9:e96246.
Garrabou G., Soriano A., Pinos T., Casanova-Molla J., Pacheu-Grau D., Moren C., et al. Influence of mitochondrial genetics on the mitochondrial toxicity of linezolid in blood cells and skin nerve fibers. Antimicrob Agents Chemother2017;61:pii:e00542-17.
Tsuji Y., Holford N.H.G., Kasai H., Ogami C., Heo Y.A., Higashi Y., et al. Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. Br J Clin Pharmacol2017;83:1758–72.
Flanagan S., McKee E.E., Das D., Tulkens P.M., Hosako H., Fiedler-Kelly J., et al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother2015;59:178–85.
